Tag Archives: ADDRESS II Phase IIb multicenter study

Merck: Results of the ADDRESS II Phase IIb multicenter study on atacicept in patients with systemic lupus erythematosus

Data presented at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting (Abstract Number: 12L) DARMSTADT, 15-Nov-2016 — /EuropaWire/ — Merck, a leading science and technology company, today announced the results of the ADDRESS II Phase IIb, … Read the full press release